US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innovate Biopharmaceuticals, Inc.

0.5600

+0.0000

Volume:- -

Turnover:- -

Market Cap:23.14M

PE:-0.69

High:0.5600

Open:0.5600

Low:0.5600

Close:0.5600

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Innovate Biopharmaceuticals, Inc.

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.innovatebiopharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/INNT/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"INNT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INNT\",,,,,undefined,":{"symbol":"INNT","market":"US","secType":"STK","nameCN":"Innovate Biopharmaceuticals, Inc.","latestPrice":0.56,"timestamp":1588363200000,"preClose":0.56,"halted":8,"volume":0,"delay":0,"floatShares":31401489,"shares":41324976,"eps":-0.811579,"marketStatus":"Not Yet Opened","change":0,"latestTime":"05-01 16:00:00 EDT","open":0.56,"high":0.56,"low":0.56,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.811579,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1746172800000},"marketStatusCode":0,"symbolChange":{"newSymbol":"NMTR","executeDate":"2020-05-04"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.56,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"INNT\",,,,,undefined,":{"symbol":"INNT","floatShares":31401489,"roa":"-258.31%","roe":"407.57%","lyrEps":-0.811579,"shares":41324976,"dividePrice":0,"high":0.56,"amplitude":0,"preClose":0.56,"low":0.56,"week52Low":0.3701,"pbRate":"4.62","week52High":1.67,"institutionHeld":0,"latestPrice":0.56,"eps":-0.811579,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.811579,"open":0.56},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.innovatebiopharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0357},{"period":"1month","weight":-0.0087},{"period":"3month","weight":-0.0835},{"period":"6month","weight":-0.0289},{"period":"1year","weight":0.1047},{"period":"ytd","weight":-0.0538}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.","exchange":"NASDAQ","name":"Innovate Biopharmaceuticals, Inc.","nameEN":"Innovate Biopharmaceuticals, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"INNT\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/INNT\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-05-08","symbol":"INNT","fiscalQuarterEnding":"2020/03","expectedEps":-0.13,"name":null,"time":"","type":"earning","dateTimestamp":1588910400000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2020-05-04","symbol":"INNT","oldSymbol":"INNT","newSymbol":"NMTR","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1588564800000},{"market":"US","date":"2020-03-20","symbol":"INNT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1584676800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2019-11-07","symbol":"INNT","fiscalQuarterEnding":"2019/09","expectedEps":-0.14,"name":null,"time":"","type":"earning","dateTimestamp":1573102800000,"reportTimeType":"","actualEps":-0.19},{"date":"2019-08-08","symbol":"INNT","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2019/06","expectedEps":-0.16,"defaultRemindTime":1565251200000,"name":null,"time":"Pre-Market","dateTimestamp":1565236800000,"actualEps":-0.16}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"INNT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"INNT\",market:\"US\",delay:false,,,undefined,":{}}}